JOURNEY LVAD: JOURNEY Left Ventricular Assist Device

NCT07363473 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-05

No results posted yet for this study

Summary

The objective of this study is to assess the safety and effectiveness of the J-Valve Transfemoral Transcatheter Heart Valve System in patients on left ventricular assist device (LVAD) support with significant native aortic valve regurgitation (AR).

Conditions

  • Aortic Valve Regurgitation
  • Aortic Valve Disease Mixed
  • Aortic Insufficiency

Interventions

DEVICE

J-Valve Transfemoral System

Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.

Sponsors & Collaborators

  • JC Medical, Inc., an affiliate of Edwards Lifesciences LLC

    lead INDUSTRY

Principal Investigators

  • Richard Cheng, MD · University of California, Los Angeles

  • Andrew Morse, MD · Ascension St. Thomas

  • Ulrich Jorde, MD · Montefiore Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-11-30
Completion
2029-11-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07363473 on ClinicalTrials.gov